Evidence map›Paper›PMID 39452270›Full record

ArticleJournal of cardiovascular development and disease2024

Cutoff Values of Aldosterone and the Aldosterone-Renin Ratio for Predicting Primary Aldosteronism in Patients with Resistant Hypertension: A Real-Life Study.

João Vicente da Silveira, Carine Sangaleti, Cleber Camacho, Ana Alice Wolf Maciel, Maria Claudia Irigoyen, Thiago Macedo, José Jayme G De Lima, Luciano F Drager, Luiz Aparecido Bortolotto, Heno Ferreira Lopes and 3 more

Abstract read
In one paragraph

Article in Journal of cardiovascular development and disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

João Vicente da SilveiraMedical School, Universidade Nove de Julho-Uninove, São Paulo 04101-200, Brazil.ORCID 0000-0002-4426-0512
Carine SangaletiNurse Department, Universidade Estadual do Centro-Oeste-Unicentro, Guarapuava 85040-167, Brazil.
Cleber CamachoMedical School, Universidade Nove de Julho-Uninove, São Paulo 04101-200, Brazil.
Ana Alice Wolf MacielUnidade de Hipertensão, Disciplina de Nefrologia-Universidade de São Paulo-HC-FMUSP, São Paulo 05403-010, Brazil.
Maria Claudia IrigoyenCardiology Department, Unidade de Hipertensão, Instituto do Coração-Universidade de São Paulo-HC-FMUSP, São Paulo 05403-000, Brazil.ORCID 0000-0003-2097-3662
Thiago MacedoCardiology Department, Unidade de Hipertensão, Instituto do Coração-Universidade de São Paulo-HC-FMUSP, São Paulo 05403-000, Brazil.
José Jayme G De LimaCardiology Department, Unidade de Hipertensão, Instituto do Coração-Universidade de São Paulo-HC-FMUSP, São Paulo 05403-000, Brazil.
Luciano F DragerCardiology Department, Unidade de Hipertensão, Instituto do Coração-Universidade de São Paulo-HC-FMUSP, São Paulo 05403-000, Brazil.ORCID 0000-0002-2081-6846
Luiz Aparecido BortolottoCardiology Department, Unidade de Hipertensão, Instituto do Coração-Universidade de São Paulo-HC-FMUSP, São Paulo 05403-000, Brazil.
Heno Ferreira LopesCardiology Department, Unidade de Hipertensão, Instituto do Coração-Universidade de São Paulo-HC-FMUSP, São Paulo 05403-000, Brazil.ORCID 0000-0002-9591-3093
Madson Q AlmeidaLaboratório de Endocrinologia Molecular e Celular LIM/25, Disciplina de Endocrinologia e Metabologia, Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo 05403-010, Brazil.
Brent M EganCardiovascular Health, American Medical Association, Medical University of South Carolina, Greenville, SC 29425, USA.
Fernanda Marciano Consolim-ColomboMedical School, Universidade Nove de Julho-Uninove, São Paulo 04101-200, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary aldosteronism (PA) is commonly associated with resistant hypertension. Biochemical tests can be clinically useful in the screening and diagnosis of primary aldosteronism. This study aimed to identify the cutoff values of aldosterone levels (A) and the aldosterone-renin ratio (ARR) for an accurate prediction of PA in patients with apparent resistant hypertension in a real-life scenario. This database-based study included a historical cohort of male and female patients with apparent resistant hypertension, aged 18 years or older and surveyed for PA in a specialized center from 2008 to 2018. Aldosterone and plasma renin activity (PRA) or the plasma renin concentration (PRC) were measured in the treated hypertensive patients. The patients with positive screening results were subsequently referred to the endocrinology department for confirmatory tests. The patients with confirmed PA were included in the case group, and the others remained as controls. Receiver-operating characteristic (ROC) curves were used to identify the cutoff points for aldosterone and the ARR, thereby analyzing their sensitivity and specificity for confirmed PA. Among the 3464 patients (59 ± 13 years old, 41% male) who had apparent resistance hypertension screened, PA was confirmed in 276 individuals (8%). A ≥ 16.95 ng/dL (95% CI: 0.908-0.933) had an odds ratio of 6.24 for PA, while A/PRA ≥ 29.88 (95% CI: 0.942-0.984) or an A/PRC ≥ 2.44 (95% CI: 0.978-0.990) had an odds ratio of 216.17 for PA diagnoses. Our findings suggest that a positive PA screening with aldosterone ≥ 17 ng/dL associated with A/PRA ≥ 29.88 or an A/PRC ratio of ≥2.44 should be sufficient to confirm the diagnosis of PA without confirmatory testing.

Indexed as

aldosteronealdosterone–renin ratioapparently resistant hypertensionprimary aldosteronismreference valuesecondary hypertension

Identifiers

PMID39452270
PMCPMC11508297

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.